BIO-RAD

Welcome to the Brand page for “BIO-RAD”, which is offered here for Electrophoresis imaging instruments; preparative electrophoresis instrument and cells; pulsed-filed electrophoresis instruments; nucleic acid sequencing cells; blotting cells and membranes for electrophoretic transfer; microfiltration units for laboratory use; particle delivery guns for in vivo gene transfer; gel documentation instruments; electroporation instruments; computerized biochemical imaging instruments and densitometers; biochemical microplate readers; pipet tips, test tubes and pipeting instruments; computer programs for biochemical imaging and analysis, and for biochemical laboratory quality; hemoglobin testing instruments and parts therefor; dna analyzer instruments; instruments for medical amino acids testing; instruments for infectious disease testing; computerized neo-natal screening instruments;reagents and chemicals for clinical, medical, and diagnostic uses, reagents and chemicals for hemoglobin testing, therapeutic drug monitoring, serum testing, urine testing, drug of abuse testing, and blood testing;bio rad;chromatography chemical standards; ion exchange chromatography support resins and gels, support resins for high-pressure liquid chromatography, size exclusion and affinity chromatography; reagents and chemicals for medical and scientific research use, reagents for affinity chromatography; reagents for capillary chromatography; gels, reagents, chemical standards, stains, and tracking dyes for electrophoresis; reagents for preparative electrophoresis; biochemicals for mutagenesis and electrophoretic blotting; chemicals used for nucleic acid purification, amplification and detection; live cells for electroporation; reagents for biochemical imaging and analysis; chemicals for biochemical assays, immunoassay;medical equipment, drug profiling and drug monitoring instruments;.

Its status is currently believed to be active. Its class is unavailable. “BIO-RAD” is believed to be currently owned by “Bio-Rad Laboratories, Inc.”